These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 2084948

  • 61. Regulation of murine splenocyte responses by heparan sulfate.
    Wrenshall LE, Cerra FB, Carlson A, Bach FH, Platt JL.
    J Immunol; 1991 Jul 15; 147(2):455-9. PubMed ID: 1830063
    [Abstract] [Full Text] [Related]

  • 62. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J, Walenga JM, Pifarre R, Hoppensteadt D, Koza M.
    Haemostasis; 1991 Jul 15; 21 Suppl 1():64-72. PubMed ID: 1894198
    [Abstract] [Full Text] [Related]

  • 63. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR, Nazareth RA, Mourão PA.
    Thromb Haemost; 2001 Dec 15; 86(6):1540-6. PubMed ID: 11776325
    [Abstract] [Full Text] [Related]

  • 64. Normal and low molecular weight heparins: interaction with human platelets.
    Fabris F, Fussi F, Casonato A, Visentin L, Randi M, Smith MR, Girolami A.
    Eur J Clin Invest; 1983 Apr 15; 13(2):135-9. PubMed ID: 6223824
    [Abstract] [Full Text] [Related]

  • 65. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J, Ofosu F, Buchanan M.
    Semin Thromb Hemost; 1985 Jan 15; 11(1):13-6. PubMed ID: 2579436
    [Abstract] [Full Text] [Related]

  • 66. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A, Dawes J.
    Thromb Haemost; 1994 Jun 15; 71(6):759-67. PubMed ID: 7526481
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II.
    Sie P, Dupouy D, Caranobe C, Petitou M, Boneu B.
    Blood; 1993 Apr 01; 81(7):1771-7. PubMed ID: 8461463
    [Abstract] [Full Text] [Related]

  • 69. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA, Choay J, Anvari N, Smith LM, Blajchman MA.
    Eur J Biochem; 1990 Oct 24; 193(2):485-93. PubMed ID: 2226466
    [Abstract] [Full Text] [Related]

  • 70. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F, Petitou M, Choay J, Sie P, Houin G, Boneu B.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Oct 24; 116(6):851-7. PubMed ID: 2483702
    [Abstract] [Full Text] [Related]

  • 71. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L, D'Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB.
    Thromb Haemost; 1996 Dec 24; 76(6):1102-7. PubMed ID: 8972038
    [Abstract] [Full Text] [Related]

  • 72. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI.
    Circulation; 1997 Jan 07; 95(1):118-24. PubMed ID: 8994426
    [Abstract] [Full Text] [Related]

  • 73. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
    Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR.
    Thromb Haemost; 1989 Feb 28; 61(1):7-9. PubMed ID: 2473537
    [Abstract] [Full Text] [Related]

  • 74. Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin.
    Hoppensteadt DA, Gray A, Jeske WP, Walenga JM, Fareed J.
    Clin Appl Thromb Hemost; 2014 Sep 28; 20(6):621-8. PubMed ID: 23482722
    [Abstract] [Full Text] [Related]

  • 75. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.
    Dol F, Caranobe C, Dupouy D, Petitou M, Lormeau JC, Choay J, Sié P, Boneu B.
    Thromb Res; 1988 Oct 15; 52(2):153-64. PubMed ID: 3194890
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.
    Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama M.
    Thromb Haemost; 1995 Nov 15; 74(5):1384-5. PubMed ID: 8607131
    [No Abstract] [Full Text] [Related]

  • 79. Modulation of proteoglycan synthesis by bovine vascular smooth muscle cells during cellular proliferation and treatment with heparin.
    Williams SP, Mason RM.
    Arch Biochem Biophys; 1991 Jun 15; 287(2):386-96. PubMed ID: 1716868
    [Abstract] [Full Text] [Related]

  • 80. Heparin and heparan sulfate binding sites on B-16 melanoma cells.
    Biswas C.
    J Cell Physiol; 1988 Jul 15; 136(1):147-53. PubMed ID: 2840440
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.